Corticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial

Journal of the American Society of Nephrology

Volumn 15, Issue 1, 2004, Pages 157-163

  Pozzi, Claudio ^a   Andrulli, Simeone ^a   Del Vecchio, Lucia ^a   Melis, Patrizia ^b   Fogazzi, Giovanni B ^c   Altieri, Paolo ^b   Ponticelli, Claudio ^c   Locatelli, Francesco ^a  

^a A MANZONI HOSPITAL   (Italy)

^b BROTZU HOSPITAL   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METHYLDOPA; METHYLPREDNISOLONE; PREDNISONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG EFFICACY; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 0346734162     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000103869.08096.4F     Document Type: Article

References (28)

1. D'Amico G: Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors. Am J Kidney Dis 36: 227-37, 2000
2. Koyama A, Igarashi M, Kobayashi M, Members and Coworkers of the Research Group on Progressive Renal Diseases: Natural history and risk factors for immunoglubin A nephropathy in Japan. Am J Kidney Dis 4: 526-532, 1997
3. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux C, JM, F: Prognostic factors in mesangial IgA glomerulonephritis: An extensive study with univariate and multivariate analysis. Am J Kidney Dis 18: 12-19, 1991
4. Donadio JV, Bergstralh EJ, Offord KP, Holley KE, Spencer DC: Clinical and histopathological associations with impaired renal function in IgA nephropathy. Clin Nephrol 41: 65-71, 1994
5. D'Amico G, Colasanti G, Barbiano di Belgioiso G, Fellin G, Ragni A, Egidi F, Radaelli L, Fogazzi G, Ponticelli C, Minetti L: Long-term follow-up of IgA mesangial nephropathy: Clinicohistological study in 374 patients. Semin Nephrol 4: 355-358, 1987
6. Bartosik LP, Lajoie G, Sugar L, Cattran DC: Predicting progression in IgA nephropathy. Am J Kidney Dis 38: 728-735, 2001
7. Syrjanen J, Mustonen J, Pasternack A: Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 15: 34-42, 2000
8. Li PK, Ho KK, Szeto CC, Yu L, Lai FM: Prognostic indicators of IgA nephropathy in the Chinese-Clinical and pathological perspectives. Nephrol Dial Transplant 17: 64-69, 2002
9. Rauta V, Finne P, Fagerudd J, Rosenlof K, Tornroth T, Gronhagen-Riska C: Factors associated with progression of IgA nephropathy are related to renal function - a model for estimating risk of progression in mild disease. Clin Nephrol 58: 85-94, 2002
10. Daniel L, Saingra Y, Giorgi R, Bouvier C, Pellissier JF, Berland Y: Tubular lesions determine prognosis of IgA nephropathy. Am J Kidney Dis 35: 13-20, 2000
11. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S: Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 72: 237-242, 1996
12. Kobayashi Y, Fujii K, Hiki Y, Tateno S: Steroid therapy in IgA nephropathy: A prospective pilot study in moderate proteinuric cases. Q J Med 234: 935-943, 1986
13. Kobayashi Y, Fujii K, Hiki Y, Tateno S, Kurokawa A, Kamiyama M: Steroid therapy in IgA nephropathy: A retrospective study in heavy proteinuric cases. Nephron 48: 12-17, 1988
14. Julian B, Barker C: Alternate-day prednisone therapy in IgA nephropathy: Preliminary analysis of a prospective randomized controlled trial. Contrib Nephrol 104: 198-206, 1993
15. Lai KN, Lai FM, Ho CP, Chan KW: Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: A long-term controlled trial. Clin Nephrol 26: 174-180, 1986
16. Welch TR, Fryer C, Shely E, Witte DP, Quinlan M: Double-blind, controlled trial of short-term prednisone therapy in immunoglobulin A glomerulonephritis. J Pediatr 121: 474-477, 1992
17. Waldo FB, Wyatt RJ, Kelly DR, Herrera GA, Benfield MR, Kohaut EC: Treatment of IgA nephropathy in children: Efficacy of alternate-day oral prednisone. Pediatr Nephrol 7: 529-532, 1993
18. Shoji T, Nakanishi I, Suzuki A, Hayashi T, Togawa M, Okada N, Imai E, Hori M, Tsubakihara Y: Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. Am J Kidney Dis 35: 194-201, 2000
19. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F: Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 353: 883-887, 1999
20. Bogenschutz O, Bohle A, Batz C, Wehrmann M, Pressler H, Kendziorra H, Gartner HV: IgA nephritis: On the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. Am J Nephrol 10: 137-147, 1990
21. Johnston PA, Brown JS, Braumholtz DA, Davison AM: Clinicopathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy: A report from the MRC glomerulonephritis registry. Q J Med 84: 619-627, 1992
22. Katafuchi R, Oh Y, Hori K, Komota T, Yanase T, Ikeda K, Omura T, Fujimi S: An important role of glomerular segmental lesions on progression of IgA nephropathy: A multivariate analysis. Clin Nephrol 41: 191-198, 1994
23. Donadio JV, Grande JP: Immunoglobulin A nephropathy: A clinical perspective. J Am Soc Nephrol 8: 1324-1332, 1997
24. Radford MG, Donadio JV, Bergstralh EJ, Grande JP: Predicting renal outcome in IgA Nephropathy. J Am Soc Nephrol 8: 199-207, 1997
25. Coppo R, Amore A, Gianoglio B, Cacace G, Picciotto G, Roccatello D, Peruzzi L, Piccoli G: Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis 21: 593-602, 1993
26. Dillon JJ: ACE inhibitor therapy: A meta-analysis [Abstract]. J Am Soc Nephrol 9: 86A, 1998
27. Locatelli F, Pozzi C, Del Vecchio L, Bolasco PG, Fogazzi GB, Andrulli S, Melis P, Altieri P, Ponticelli C: Role of proteinuria reduction in the progression of IgA nephropathy. Ren Fail 23: 495-505, 2001
28. Ponticelli C, Zucchelli P, Passerini P, Cesana B: Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. N Engl J Med 327: 599-603, 1992